XSHG
600196
Market cap9.37bUSD
Oct 09, Last price
23.89CNY
1D
0.55%
1Q
1.88%
Jan 2017
3.29%
Name
Shanghai Fosun Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Related entities
Subsidiaries
Chindex Hong Kong Limited
Key people
Yuqing Chen
Executive Chairman of the Board · since 2025
Kexin Wang
Executive Co-Chairman of the Board · since 2022
Jing Li
Co-President, Chief Executive Officer - Established Medicines and Manufacturing & Supply Division · since 2025
Xingli Wang
Co-President, Chief Executive Officer - Global R&D Center, Co-Chief Executive Officer - Innovative Medicine Division · since 2025
Wenjie Zhang
Co-President, Co-Chief Executive Officer - Innovative Medicine Division · since 2025
Zhanyu Chen
Chief Financial Officer, Senior Vice President · since 2024
Rongli Feng
Executive President, Chief Human Resources Officer · since 2024
Hang Hu
Senior Vice President · since 2022
Xiang Li
Senior Vice President, Co-President & Chief Scientific Officer - Innovative Pharmaceuticals Division, Co-President - Global R&D Center · since 2025
Donghua Wang
Senior Vice President · since 2025
Xiaoxian Dong
Vice President, Secretary of the Board, Joint Company Secretary · since 2016
Hao Ji
Vice President, General Manager- Anti-Corruption Supervision Department · since 2022
Lilang Lu
Vice President, Co-Chief Executive Officer - Medical Devices Division · since 2023
Lingyuan Meng
Vice President · since 2026
Li Su
Vice President, Executive President - Established Medicines and Manufacturing & Supply Division · since 2022
Fangbing Yuan
Vice President · since 2025
Yue Zhu
Vice President, General Manager - Legal Department · since 2022
Xiaohui Guan
Executive Co-Chairman of the Board · since 2025
President, Chief Executive Officer, Chairman and Chief Executive Officer - Medical Devices Division, Chairman - Medical Diagnosis Division, Executive Director · since 2025
Chief Executive Officer, Executive Director · since 2022
Headquarters & legal address
曹杨路510号9楼
普陀区, SH 100000
CN
普陀区, SH 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||